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Case Report
AbstractDesmoid tumor represents a rare monoclonal, fibroblastic proliferationcharacterized by a variable and often unpredictable clinical course. Althoughhistologically benign, desmoids are locally invasive and associated with a high localrecurrence rate, but lack of metastatic potential. Many issues regarding the optimaltreatment of patients with desmoids remain controversial. Surgical resection andradiotherapy are standard treatment options for these patients. Due toheterogeneity of the biological behavior of desmoids, including long periods ofstable disease or even spontaneous regression, treatment needs to beindividualized to optimize local tumor control and preserve patient's quality of life.Therapeutic approaches to the treatment of recurrent or unresectable desmoidtumors comprise anti-hormonal therapy, non-steroidal anti-inflammatory drugs,classic chemotherapy regimens and tyrosine kinase inhibitor, with highly variableresults. It has not yet been possible to establish an optimal therapy protocol for thisdisease. In this case report we present our experience with the treatment ofrecurrent extra-abdominal desmoid tumor.
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1. IntroductionDesmoid tumors (DT), also known as aggressivefibromatosis or musculoaponeurotic fibromatosis, arefibroblastic tumors of intermediate malignant potential.They are characterized by slow growth, tendency forlocal recurrence and absence of metastatic potential.The term “desmoid”, coined by Muller in 1838, isderived from the Greek word “desmos”, meaningtendon-like. DTs are extremely rare and account for lessthan 0.03% of all tumors1. Surgical resection andradiotherapy are standard treatment options for thesepatients2-4. Recurrence rate is high during DTmanagement. Systemic treatment with Imatinib forunresectable or recurrent DTs could be acceptabletherapeutic option5.This report depicts a case of extra-abdominal DT of thegluteal region in a 43-year-old female who has reportedto the oncologist for further treatment after a surgicalresection and a year after subsequent diseaserecurrence. The goal of this case report is to providebetter insight in treatment options of this rare disease
and to emphasize the importance of multidisciplinaryapproach in the treatment of such patients.
2. Case PresentationA 43-year-old female underwent surgical resection ofthe tumor in the right gluteal region at the OrthopedicClinic in September 2010. Tumor was previouslydiagnosed by MRI scan. Upon surgical examination ofthe pelvic region, the tumor was found to be locatedbetween the right medial and large gluteal muscles,anterior and caudal to greater trochanter. Differentialdiagnosis suggested aggressive fibromatosis. Totalextirpation of tumor was performed, and upon receivinga pathology report, patient was not referred to theoncologist. In January 2011, the patient reported againto her orthopedic surgeon due to pain she wasexperiencing in the surgical scar region, which radiatedalong the front of the thigh and lower leg. Control MRIperformed in April 2011 revealed three locations of localrecurrence: a mass 15×43×15 mm in size locatedbetween the two gluteal muscles - right gluteus medius
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and maximus; second mass with maximum dimensions45×120×25 mm located under the subcutaneous fattytissues from anterior iliac crest and caudal to greatertrochanter of the right hip; and the third mass 18x36x15mm in size posterior in the middle third from thepreviously described mass (Figure 1). A smaller tumormass sized 14×22×8 mm was described in ischioanalfossa, clearly differentiated from the surrounding tissuewith intensive post-contrast enhancement, with threeadditional lesions, 20×8 mm, 21×8 mm and 9×2 mm insize in the right internal obturator muscle. At this time,orthopedic surgeon recommended another control MRIin 6 months.
Figure 1: MRI scan performed in April 2011 showing threelocations of disease recurrence.Patient was referred to the oncologist for the first timein May 2012. Retrospective inspection of medicalrecords and pathology report revealed that the patienthad desmoid fibromatosis with low mitotic activity, withtumor cells positive for vimentin, SMA, myoglobin, andnegative for desmin, MyoD1, with low proliferative Ki67positivity but with tumor cells present at the resectionmargins. Patient was advised to repeat an MRI and toconsult an orthopedist and a neurosurgeon. A controlMRI performed in May 2012 revealed a progression ininternal obturator muscle, with a possible infiltration oflevator ani muscle (Figure 2). Orthopedic surgeon and aneurosurgeon were consulted and have advised againstrepeated surgical procedure due to the size of recurrenttumor mass. A multidisciplinary team held a caseconference in August 2012 and advised againstirradiation, due to high risk of radiotherapy-inducedcomplications, considering the tumor size, invasion andproximity of the sciatic nerve. Therefore, therecommended treatment was systemic therapy withhormonal agent Tamoxifen 20 mg/day and COX-IIinhibitor Celebrex 200 mg. Three months later, a controlMRI revealed signs of tumor necrosis, no further changein size and distribution of tumor lesions and no newlesions. Therefore, the same therapy was continued.Control MRI in February 2013 revealed no furtherdisease progression and the therapy remainedunchanged.
Figure 2: A control MRI performed in May 2012 describinga progressive recurrence of the disease.An MRI performed in July 2013 displayed diseaserecurrence along the lesion of the right quadratusfemoris and internal obturator muscles. Compared tothe previous MRI, some lesions were larger and somewere smaller in size, and there appeared to be a newlesion located in the right obturator internal muscle.Patient was prescribed interferon-alpha at the dose of3.500.000 IU three times a week within 6 months,considering that the patient was not motivated fortreatment with chemotherapy. Control MRI performedin March 2014 revealed that the largest lesion hadshrunk in size while the smallest lesion had grown(Figure 3). At this time point, Imatinib was added to thelist of essential medicines in Bosnia and Herzegovina, so,considering the results of the clinical trials6, the teamrecommended therapy with Imatinib. Patient initiatedImatinib therapy in April 2014. Control MRI in June2014 revealed a decrease in size of the aforementionedtumor masses and lesions. Our patient continuedtherapy with Imatinib, without serious adverse events.The latest MRI scan performed in October 2015 showedcomplete regression of some lesions, no changes in sizeof other lesions, but with lower post-contrastenhancement and complete fibrosis of the largest lesion.
Figure 3: Control MRI performed in March 2014 showingregression of one lesion and progression of the other.
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Figure 4: Control MRI performed in October 2015 showingcomplete regression of some lesions, other lesions withoutchanges in size, but with lower post-contrast enhancementand complete fibrosis of the largest lesion.
3. DiscussionWhile DT is a benign tumor, it is not necessarily a benigndisease. Within the general population, the incidence ofDT is 2-4 cases per million people annually7. Theincidence is higher in patients with familialadenomatous polyposis (FAP). DTs occur in 10-15% ofthese patients8. Its etiology is most likely multifactorialand includes genetic predisposition, endocrine factorsand trauma. There are also sporadic forms withouthereditary background. Most of the cases occur in theage between 15 and 60 years old, with the highestincidence between 25 and 35 years old3. DTs arise inconnective tissue, fascia or aponeurosis of the muscleand tend to infiltrate adjacent muscle bundles,frequently entrapping them and causing theirdegeneration9. Typical clinical presentation includes apainless, slow-growing, deep-seated mass. DTs arecommonly divided into abdominal and extra-abdominaltumors, based on their localization10, 11. DTs lack theability to metastasize, and therefore local control usingsurgery and radiation has traditionally been themainstay of therapy for these tumors. Negative marginstatus (defined as surgical resection withmicroscopically negative margins) should be achieved, ifpossible, for a patient who is treated surgically2.Radiotherapy has been incorporated into themanagement of extra-abdominal DT, either as anadjuvant treatment after surgical resection in cases ofpositive surgical margins or as a primary treatmentwhen surgical resection is not feasible or may result insignificant loss of function4. In a review published byMelis et al.12 it was suggested that surgical excision andradiotherapy in the treatment of recurrent lesionsprovide better results than surgery alone. The use ofpostoperative radiation, as described in a review of 22series13, increases the local control of the disease. Inpatients with positive margins, the local controlincreased from 4% to 75% with the addition of adjuvantirradiation. Positive effect of irradiation was alsoobserved in patients with negative surgical margins. In
case of disease relapse, there are several systemictreatment options, such as anti-hormonal therapy14,non-steroidal anti-inflammatory drugs (NSAIDs) (e.g.,cyclooxygenase [COX]-2 inhibitors)15, classicchemotherapy regimens and tyrosine kinase inhibitor(Imatinib)5. Combinations of a non-steroidalanti-inflammatory drugs and Tamoxifen are commonlyused as primary treatment of desmoids16.In a clinical trial performed by the French sarcomagroup, there were positive initial results of treatmentwith Imatinib with non-progression rates of 90% and80% at 3 and 6 months, respectively, but thesedecreased to 67% at 12 months. The median time toprogression in this study was 25 months6. These resultswere confirmed in the SARC (Sarcoma Alliance forResearch through Collaboration) trial with initialprogression-free survival of 94% and 88% at 2- and4-months follow-up appointments but these decreasedsignificantly to 66% at 1 year17. Despite the limitedpotential of Imatinib alone, there is still an increasinginterest for tyrosine kinase inhibitors in the treatment ofextra-abdominal DTs.Given the variability of the clinical course of DTs and thepotential for complications that can arise as a result oftherapy, the cases of all patients with DTs, who are aboutto undergo active treatment, should be discussed by anexperienced multidisciplinary sarcoma team, and thetreatment plan should take into consideration patientpreferences. Even though the pathology report in ourpatient showed that tumor cells were present at theresection margins, due to the lack of multidisciplinarywork, the patient did not receive radiotherapy. Ourpatient was presented for the first time at amultidisciplinary tumor board a year after diseaserelapse was diagnosed. Considering the risk ofradiotherapy-induced complications18 due to tumor size,multicentricity, invasion and proximity of sciatic nerve,the tumor board did not recommend radiotherapy.Therefore, the only treatment option was systemictherapy. There are no evidence-based or widely acceptedguidelines for management of unresectable DT. Systemictherapy is increasingly being integrated into amultidisciplinary approach for selected patients withunresectable or intra-abdominal desmoids for whichlocal therapy options may cause unacceptable morbidity.In the literature similar cases of recurrent DT have beendescribed with an excellent response to Imatinib19.
4. ConclusionAfter two lines of therapy, considering the results ofother studies, our patient received treatment withtyrosine kinase inhibitor Imatinib, which led to a goodpartial response with acceptable side effects. It isimportant to emphasize that, due to financial challengesof the health care system in Bosnia, Imatinib is onlyfinanced in patients with gastrointestinal stromal tumor
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and chronic myeloid leukemia. Our patient was the firstcase of DT in Bosnia who received this treatment. Webelieve that the most important concept in the treatmentof DT is to individualize each patient and to have amultidisciplinary approach involving the surgeon,radiation and medical oncologist, pathologist,radiologist, psychologist, occupational therapist,physiotherapist and most importantly to always takeinto account the patient’s opinion. With this case reportwe hope to contribute to better understanding of thisrare disease and that it might be a useful asset inchoosing the treatment of these patients.
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